Related Experiment Video
Updated: Jun 4, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
ALSUntangled #77: Psilocybin
Bhavya Bakshi1, Sandeep Yerraguntla1, Carmel Armon2
1Medical School, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Abstract:
ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation. Currently, there are no pre-clinical ALS models, case reports, or trials for psilocybin and ALS in the context of disease modifying therapy. Depending on dosing, there can be a high risk of psychological side effects including hallucinations and physical harm. Based on the above information, we do not currently support the use of psilocybin as a means to slow ALS progression.
Related Concept Videos
Hallucinogens and Psychedelics
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Altered States of Awareness
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
CNS Stimulants: Psychedelic Agents
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
Radical Halogenation: Stereochemistry
Halogenation to form a new chiral center:

